番茄社区

ORLANDO -- Kicking off here this Friday, the largest scientific diabetes meeting in the world will spotlight the latest advancements in diabetes medicine at the , which runs through Tuesday.

Promising over 2,100 posters including 47 moderated poster discussions, 375 oral presentations and nearly 300 published-only abstracts, the meeting is expected to draw over 16,000 healthcare professionals over the five-day run being held at the the Orange County Convention Center.

Major trials and late-breaking research on the newest insights to type 1 and type 2 diabetes treatments will be at the forefront of much of the packed program. Among some of the highlighted sessions to be featured throughout the meeting will include:

• Real-World Evidence in Diabetes
• Lessons Learned from the TEDDY Study: Insights into Early Autoimmune Type 1 Diabetes
• 15-year Update on the Veterans Affairs Diabetes Trial (VADT)
• The Restoring Insulin Secretion (RISE) Study in Youth and Adults: Findings from the Pediatric Medication Study
• Draft ADA/EASD Consensus Report 2018: Management of Hyperglycemia in T2D
• SGLT-I's for T1D Management: How Far Have We Gone?

Maureen A. Gannon, PhD, chair of the conference's planning committee, especially encouraged meeting-goers to stay for the meeting's final session on Tuesday, focusing on SGLT2 inhibitors for type 1 diabetes.

Buzz has been building around the pediatric outcomes from the , to be presented Monday afternoon. The trial -- which was split into adult and pediatric multicenter trials -- aimed to address whether aggressive glucose reduction with metformin alone or with basal insulin glargine (Lantus) followed by metformin in early type 2 diabetes or prediabetes could result in beta-cell recovery, and whether this recovery could be sustained after withdrawal of treatment.

In line with the theme of much of last year's data, cardiovascular disease in diabetes remains a hot-topic, particularly among many of the 300 late-breaking abstracts being presented on Monday. One of these abstracts will feature a real-world analysis of canagliflozin (Invokana) compared to other antihyperglycemic agents and their risk for below-the-knee amputation in patients with type 2 diabetes, presented by John Buse, MD, PhD, of the University of North Carolina School of Medicine. Another late-breaker will feature another analysis of the ODYSSEY trial, presented by Kausik Ray, MD, of Imperial College London, looking at cardiovascular outcomes with the PCSK9 inhibitor alirocumab (Praluent) in patients with both diabetes and acute coronary syndrome.

Type 1 diabetes won't be left out when it comes to new abstracts -- one late-breaking clinical trial, to be presented by Paresh Dandona, MD, PhD, of University at Buffalo Jacobs School of Medicine & Biomedical Sciences, will feature the 52-week outcome data assessing liraglutide (Victoza) as adjunct treatment to insulin for type 1 diabetes treatment.

Much of the research focusing on type 1 diabetes will also feature the latest advancements in technology, including glucose monitoring and sensing devices. One study in particular will present findings on the first-ever assessment of a 180-day implantable continuous glucose monitor (CGM) used in adolescents -- the Senseonics' Eversence XL CGM -- which coincidentally won FDA approval on Thursday afternoon. Another study will announce the findings of a head-to-head comparison of three CGM devices used in patients with type 1 diabetes: Dexcom G5, Abbott Freestyle Libre Pro and the Senseonics device.

"I encourage those attending this year's conference to take advantage of the breadth and depth of high-quality research topics being presented," said Gannon in a statement. "This is truly one of the strengths of the Scientific Sessions."

Follow coverage of the ADA's 78th Scientific Sessions on 番茄社区, and on Twitter , along with the hashtag .

Comment